Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
51 hedge funds and large institutions have $62M invested in Enzo Biochem, Inc. in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 11 closing their positions.
63% more call options, than puts
Call options by funds: $253K | Put options by funds: $155K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
10% less capital invested
Capital invested by funds: $69M → $62M (-$6.98M)
14% less funds holding
Funds holding: 59 → 51 (-8)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.51M |
| 2 |
PCM
Potomac Capital Management
New York
|
+$927K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$708K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$206K |
| 5 |
SFG
SNS Financial Group
Minneapolis,
Minnesota
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AE
AMH Equity
Great Neck,
New York
|
-$1.82M |
| 2 |
VCA
VIEX Capital Advisors
Sunny Isles Beach,
Florida
|
-$966K |
| 3 |
Renaissance Technologies
New York
|
-$268K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$190K |
| 5 |
Two Sigma Advisers
New York
|
-$164K |
ENZ Hedge Fund Activity: Q1 2022 in Review
51 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q1 2022, worth a combined $62M — down 10% from $69M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ENZ and 3 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 13 added.
The largest buyer was Morgan Stanley, adding an estimated $1.51M. The largest seller was AMH Equity, cutting an estimated $1.82M.
- 51 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q1 2022, down from 59 in Q4 2021.
- Funds reported $62M of Enzo Biochem, Inc. stock for Q1 2022, down 10% quarter-over-quarter.
- 3 funds opened new Enzo Biochem, Inc. positions in Q1 2022 and 11 closed out, a net change of -8 holders.
- The largest Enzo Biochem, Inc. buyer in Q1 2022 was Morgan Stanley, an estimated $1.51M added.
- The largest Enzo Biochem, Inc. seller in Q1 2022 was AMH Equity, an estimated $1.82M sold.
Based on aggregated 13F filings for Q1 2022.